Lokelma efficacy?

Lokelma (sodium zirconium cyclosilicate) is a potassium-binding resin used to treat hyperkalemia. In short, it is effective at lowering serum potassium quickly and maintaining that reduction with ongoing therapy.

Key points on efficacy
- Onset and speed: Potassium begins to fall within hours of starting treatment, with a meaningful reduction typically seen by 24 hours.
- Magnitude: In pivotal trials, reductions averaged around 1 mmol/L (about 0.9–1.0 mEq/L) from baseline within the first 24 hours, with greater reductions at higher doses.
- Dose dependence and maintenance: The effect is dose-dependent. After initial correction, continuing Lokelma at a maintenance dose helps keep potassium in the normal range (3.5–5.0 mmol/L) over weeks.
- Populations studied: Efficacy has been demonstrated in adults with hyperkalemia, including those with CKD and patients on renin–angiotensin–aldosterone system inhibitors.

Dosing (general, for context)
- Initial/acute management: Often 10 g three times daily for up to 48 hours until potassium normalizes.
- Maintenance: Then 5–10 g once daily (titrated to achieve and maintain normokalemia). The label provides 5–15 g/day dosing in increments, up to a maximum daily dose as specified on the package/label.
- Important: Not for emergency treatment of life-threatening hyperkalemia. Use standard emergency care as needed.

Safety notes
- Common adverse effects: edema, constipation, nausea, and diarrhea.
- Watch for hypokalemia if overtreated or used with other potassium-lowering therapies.
- Some drug interactions via gut binding—separate Lokelma from other oral meds as advised by the label.

Would you like a more detailed summary of a specific trial (e.g., HARMONIZE) or dosing guidance tailored to a particular patient population (CKD stage, RAAS inhibitor use, etc.)?